Shares of the small-cap biotech Agenus (NASDAQ: AGEN) rose by as much as 11.2% yesterday on over four times the average daily volume. As a result, the stock is now up by a whopping 44% for the year.
What's going on? Investors appear to be warming up to the possibility that Agenus' broad pipeline of anti-cancer checkpoint inhibitors might be deeply undervalued. The company, after all, has licensing deals with bothIncyte and Merck to develop checkpoint antibodies for a range of solid tumors.
Agenus stock has been one of the few big biotech winners in February so far -- even though the company hasn't released much in terms of news flow. This move higher seems to be backed by a solid change in sentiment toward the company's prospects at actually transforming into a leading immuno-oncology company.
The downside is that Agenus isn't expected to file for a regulatory approval for one of its checkpoint antibodies until 2019 at the earliest. That's particularly problematic because there are literally hundreds of similar therapies in development, at the moment.
Stated simply, Agenus may turn out to be developing nothing more than so-called "me-too" drugs with limited commercial upside potential. In that case, the biotech's present market cap of around $480 million is probably unwarranted. That's not to say that Agenus can't eventually strike gold with its checkpoint-inhibitor pipeline, but there's also the very real chance that the market will be saturated with competitors within the next two to three years.
10 stocks we like better than Agenus
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Agenus wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of February 5, 2018